What are the use restrictions and dose modifications of icosapent for patients with atrial fibrillation or flutter?
The use of icosapent is associated with an increased risk of hospitalization for atrial fibrillation or flutter. In addition, a non-significant trend towards a higher incidence of hospitalization for serious bleeding events was also observed. Patients should refer to the product prescribing insert for more information regarding use restrictions, dose modification, and dosing in special populations such as those with renal or liver impairment, advanced age, pregnancy, etc.